Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

acesionpharma.com

Founded Year

2011

Stage

Series B | Alive

Total Raised

$17.7M

Last Raised

$10.1M | 6 yrs ago

About Acesion Pharma

Acesion Pharma is a Danish biotech company developing more efficacious and safer drugs for the medical treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.

Acesion Pharma Headquarters Location

Ole Maaløes Vej 3

Copenhagen, DK-2200,

Denmark

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Acesion Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Acesion Pharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Acesion Pharma Patents

Acesion Pharma has filed 4 patents.

The 3 most popular patent topics include:

  • Beta blockers
  • Calcium channel blockers
  • Cardiac arrhythmia
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/23/2017

3/15/2022

Ion channels, Calcium channel blockers, Beta blockers, Cardiac arrhythmia, Sodium channel blockers

Grant

Application Date

2/23/2017

Grant Date

3/15/2022

Title

Related Topics

Ion channels, Calcium channel blockers, Beta blockers, Cardiac arrhythmia, Sodium channel blockers

Status

Grant

Latest Acesion Pharma News

Global Atrial Fibrillation Pipeline Insight Report 2021 - ResearchAndMarkets.com

Feb 16, 2021

February 16, 2021 05:52 AM Eastern Standard Time This "Atrial Fibrillation - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Atrial Fibrillation Emerging Drugs Chapters This segment of the Atrial Fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Atrial Fibrillation Emerging Drugs Etripamil: Milestone Pharmaceuticals Etripamil, the Company's lead investigational product, is designed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray, which may shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials underway in PSVT, and plans to commence a Phase 2 proof-of-concept trial in patients with atrial fibrillation with rapid ventricular rate, with subsequent studies expected in other conditions where calcium channel blockers are used. OMT 28: OMEICOS Therapeutics OMT-28 is a stable synthetic small molecule analog of the natural omega-3 fatty acid metabolite 17, 18-EEQ, which has a structure optimized to provide efficacy, safety, and oral availability. The compound has proven its anti-arrhythmic, cardioprotective, and anti-fibrotic potential in different in vivo models. Currently, it is in phase 2 of clinical trials for the treatment of atrial fibrillation. HBI-3000 (sulcardine sulfate trihydrate) : HUYA Bioscience International HBI-3000 (sulcardine sulfate trihydrate; Bai, et al. 2012) is a multi-ion channel blocker with effects on INa-Peak, INa-Late, ICa,L, and IKr with similar in vitro potencies across these various ion channels in human atrial cardiomyocytes. It is being developed by HUYA Bioscience International (HUYABIOT) for the conversion of recent onset atrial fibrillation (AF). Currently undergoing phase 1 of clinical trials. AP 30663: Acesion Pharma It is based on inhibition of SK channels - ion channels present in the atria that play a role in regulating the cardiac rhythm. Blocking these ion channels with a functionally atrial selective drug helps avoid deleterious effects on the ventricles. Targeting the SK channels thereby constitutes a novel and promising approach for an effective treatment for AF with an expected higher safety and tolerability profile. Atrial Fibrillation: Therapeutic Assessment This segment of the report provides insights about the different Atrial Fibrillation drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Atrial Fibrillation There are approx. 5+ key companies which are developing the therapies for Atrial Fibrillation. The companies which have their Atrial Fibrillation drug candidates in the mid to advanced stage, i.e. Phase II include, Acesion Pharma and others. The report covers around 5+ products under different phases of clinical development like Late-stage products (Phase III) Early-stage products (Phase I/II and Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Small molecules

  • When was Acesion Pharma founded?

    Acesion Pharma was founded in 2011.

  • Where is Acesion Pharma's headquarters?

    Acesion Pharma's headquarters is located at Ole Maaløes Vej 3, Copenhagen.

  • What is Acesion Pharma's latest funding round?

    Acesion Pharma's latest funding round is Series B.

  • How much did Acesion Pharma raise?

    Acesion Pharma raised a total of $17.7M.

  • Who are the investors of Acesion Pharma?

    Investors of Acesion Pharma include Novo Seeds, Wellcome Trust, SEED Capital, Broadview Ventures, Innovation Fund Denmark and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.